Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products:
Related news for (IMMX)
- 24/7 Market News Snapshot 06 October, 2025 – Immix Biopharma, Inc. Common Stock (NASDAQ:IMMX)
- Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
- Immix Biopharma Attends FDA CEO Forum in Washington DC
- Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
- Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
